leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.
(
CSE:AGNOTCQB:AGNPF
)

Algernon Pharmaceuticals begins screening patients for Phase 2 chronic cough and IPF study

Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has begun screening patients in Australia for a Phase 2 idiopathic pulmonary fibrosis and chronic cough clinical study with their repurposed drug Ifenprodil.

Algernon shared details about that study and he also takes a broader look at the drug Ifenprodil and the number of studies they are undertaking to see it’s effectiveness in treating respiratory conditions

Quick facts: Algernon Pharmaceuticals Inc.

Follow
CSE:AGN

Price: 0.09 CAD

Market Cap: $15.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharmaceutical’s preclinical study of DMT for stroke confirms...

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has confirmed in a preclinical study, that increased the growth of cortical neurons by 40% with statistical significance in one arm of the study. That was achieved with a sub...

1 week, 2 days ago

2 min read